Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07625332 Galantamine Hydrobromide Metabolic Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07625332 clinical trial report covering Galantamine Hydrobromide, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07718126 Mazdutide Metabolic Dysfunction Associated Steatohepatitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07718126 clinical trial report covering Mazdutide, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07718737 AMT-116(Multitude Therapeutics) metastatic non-small cell lung cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07718737 clinical trial report covering AMT-116(Multitude Therapeutics), Phase 2/3, endpoints, sponsor, geography, readout timing and development white
Latest Hotspot
8 min read
NCT07721324 Melatonin Neurolytic Block Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07721324 clinical trial report covering Melatonin, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07721545 Cilostazol/Decanol Median Cleft Lip, Corpus Callosum, Lipoma, and Skin Polyps Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07721545 clinical trial report covering Cilostazol/Decanol, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07723963 Cannabidiol Myoclonic Epilepsy, Juvenile Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07723963 clinical trial report covering Cannabidiol, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07722728 Cariprazine hydrochloride Schizophrenia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07722728 clinical trial report covering Cariprazine hydrochloride, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07722611 Bomedemstat Polycythemia Vera Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07722611 clinical trial report covering Bomedemstat, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07724457 Etoposide High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07724457 clinical trial report covering Etoposide, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07727252 Eplerenone Cardio-Renal Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07727252 clinical trial report covering Eplerenone, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07725523 Zopocianine Prostatic Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07725523 clinical trial report covering Zopocianine, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07730723 Nicorandil Rheumatoid Arthritis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07730723 clinical trial report covering Nicorandil, Phase 2/3, endpoints, sponsor, geography, readout timing and development white space.